

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2020/245420 A9

(43) International Publication Date
10 December 2020 (10.12.2020)

WIPO | PCT

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/00 (2006.01)

(21) International Application Number:

PCT/EP2020/065716

(22) International Filing Date:

05 June 2020 (05.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/858,806 07 June 2019 (07.06.2019) US

(71) Applicant: **ARGENX BVBA** [BE/BE]; Industriepark Zwi-
jnaarde 7, B-9052 Zwijnaarde (BE).

(72) Inventor: **BORGIONS, Filip**; Industriepark Zwijnaarde 7,
B-9052 Zwijnaarde (BE).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury
Square House, 8 Salisbury Square, London Greater London
EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINIS-
TRATION


X-axis: Shear rate γ [1/s]Left Y-axis: Viscosity η [Pa·s]Right Y-axis: Shear stress τ [Pa]

Fig. 1

(57) Abstract: Provided are various aqueous formulations of the neonatal Fc receptor (FcRn) antagonist ARGX-113, including formulations useful as pharmaceutical compositions, methods for their preparation, devices comprising the various formulations, and uses thereof. In certain embodiments the formulations are suitable and useful for administration of ARGX-113 to a human subject. In certain embodiments the formulations are suitable and useful for subcutaneous administration of ARGX-113 to a human subject. The formulations can be used in the treatment of any condition that would benefit from inhibition of FcRn-mediated antibody recycling. Such conditions can include any one or more of various antibody-mediated autoimmune diseases, including, for example and without limitation, myasthenia gravis (MG) and immune thrombocytopenia (ITP).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

29 April 2021 (29.04.2021)

(15) Information about Correction:

see Notice of 29 April 2021 (29.04.2021)